Saxenda at two months: what liraglutide actually does to your weight
Quick answer
The creator documents two months of liraglutide 3.0 mg (Saxenda) use for weight loss, with hashtags suggesting an underlying concern about insulin resistance. Liraglutide is an approved GLP-1 receptor agonist that produces modest, gradual weight reduction averaging 8 percent over 56 weeks per the SCALE trials, with secondary benefits for insulin sensitivity. Concurrent resistance training, referenced via gym hashtags, is clinically relevant for preserving lean mass during GLP-1-assisted weight loss.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @siby3p actually say?
Honestly, the transcript here is largely inaudible or garbled, so pinning down specific claims is difficult. What we can work with is the video caption: two months on Saxenda (liraglutide), progress described as "vamos lento pero bien" (going slow but good), paired with hashtags referencing insulin resistance, diabetes, gym work, and weight loss. That framing, slow and steady progress on a GLP-1 medication combined with exercise, is actually a reasonable way to describe a liraglutide journey. The creator is not making dramatic cure claims. They appear to be documenting a personal experience.
Given the caption context, the implicit claims are: Saxenda causes gradual weight loss, it can be used alongside gym training, and it has relevance to insulin resistance. Those are the claims worth examining.
Does the science back this up?
Yes, largely. Liraglutide at 3.0 mg (the Saxenda dose) does produce gradual, modest weight loss in most people, and the evidence supports this being the expected pattern rather than a flaw. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed participants lost an average of 8 percent of body weight over 56 weeks, compared to about 2.6 percent with placebo. That is meaningful, but it is not dramatic, and it does accumulate slowly over months.
On insulin resistance: liraglutide improves insulin sensitivity as a secondary effect, documented in the SCALE trials and supported by Wadden et al., 2013 (Obesity). The gym hashtag is relevant too. Combining GLP-1 therapy with resistance training helps preserve lean muscle mass during weight loss, which is a real concern with these medications (Lundgren et al., 2023, Obesity Reviews). The creator pairing Saxenda with gym work is not just aesthetic, it is clinically smart.
What did they get wrong (or right)?
Based on available context, the creator got the core framing right. "Slow but good" is an accurate description of what liraglutide typically delivers. Where this video could mislead by omission is the dropout rate. The SCALE trials showed around 25 to 30 percent of participants discontinued due to side effects, primarily nausea and gastrointestinal symptoms. A progress video that only shows continued use implicitly suggests tolerability that is not universal.
There is also no mention of the dose titration protocol, which matters. Saxenda is started at 0.6 mg daily and increased weekly to 3.0 mg. Skipping that context means viewers watching this as a guide might not understand why their own experience differs. That said, this appears to be a personal diary post, not a medical guide, and the creator is not prescribing anything or making efficacy claims beyond their own experience. That is a meaningful distinction.
- Accurate: gradual weight loss framing matches clinical data
- Accurate: combining with gym work is supported by evidence
- Missing context: side effect rates and dose titration not addressed
- Missing context: liraglutide is less potent than newer GLP-1 agents like semaglutide
What should you actually know?
Saxenda (liraglutide 3.0 mg) is an older GLP-1 receptor agonist approved for weight management. It works. But compared to semaglutide (Wegovy) and tirzepatide (Zepbound), it produces less weight loss on average. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieving up to 22.5 percent body weight reduction, versus roughly 8 to 10 percent for liraglutide. That is not a knock on the creator, it is context anyone considering these medications deserves.
Insulin resistance and prediabetes are legitimate indications adjacent to liraglutide use. The medication does not cure insulin resistance, but it can improve it as part of a broader lifestyle intervention. If you are considering any GLP-1 therapy, that decision should involve a clinician who can assess your full health picture, not just a TikTok comment section. Two months in is also not enough time to evaluate long-term outcomes. Most clinical trials run 52 to 68 weeks for a reason.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda at two months: what liraglutide actually does to your weight, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda at two months: what liraglutide actually does to your weight is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator documents two months of liraglutide 3.
FormBlends verdict
The creator documents two months of liraglutide 3.0 mg (Saxenda) use for weight loss, with hashtags suggesting an underlying concern about insulin resistance. Liraglutide is an approved GLP-1 receptor agonist that produces modest, gradual weight reduction averaging 8 percent over 56 weeks per the SCALE trials, with secondary benefits for insulin sensitivity. Concurrent resistance training, referenced via gym hashtags, is clinically relevant for preserving lean mass during GLP-1-assisted weight loss.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator documents two months of liraglutide 3.0 mg (Saxenda) use for weight loss, with hashtags suggesting an underlying concern about insulin resistance. Liraglutide is an approved GLP-1 receptor agonist that produces modest, gradual weight reduction averaging 8 percent over 56 weeks per the SCALE trials, with secondary benefits for insulin sensitivity. Concurrent resistance training, referenced via gym hashtags, is clinically relevant for preserving lean mass during GLP-1-assisted weight loss.
- Pi-Sunyer et al. (2015, NEJM): liraglutide 3.0 mg produces roughly 8 percent body weight loss over 56 weeks, meaning slow progress at two months is normal, not a failure.
- Jastreboff et al. (2022, NEJM): tirzepatide achieves up to 22.5 percent body weight reduction, making liraglutide one of the less potent options currently available.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Pi-Sunyer et al. (2015, NEJM): liraglutide 3.0 mg produces roughly 8 percent body weight loss over 56 weeks, meaning slow progress at two months is normal, not a failure.
- Jastreboff et al. (2022, NEJM): tirzepatide achieves up to 22.5 percent body weight reduction, making liraglutide one of the less potent options currently available.
- Lundgren et al. (2023, Obesity Reviews): GLP-1 medications can reduce lean muscle mass during weight loss, which is why pairing with resistance training is clinically meaningful, not just cosmetic.
- SCALE trial data shows 25 to 30 percent of participants discontinue liraglutide due to gastrointestinal side effects, a reality personal progress videos rarely capture.
- Saxenda requires a weekly dose titration from 0.6 mg to 3.0 mg over five weeks; skipping this context in content can mislead viewers about expected timelines and tolerability.
- Liraglutide improves insulin sensitivity as a secondary effect of weight loss, but it does not cure or independently reverse insulin resistance.
- Two months is within the early titration window for liraglutide. Most clinical protocols require 52 to 68 weeks to assess meaningful metabolic outcomes.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
siby3p · TikTok creator
216.9K views on this video
dos meses con saxenda, vamos lento pero bien #saxenda #liraglutida #liraglutide #adelgazar #dieta #inyeccion #bajardepeso #gimnasio #gym #cambiofisico #insulinresistance #insulina #diabetes
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by siby3p, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.